Nasdaq · Healthcare
ALNYLAM PHARMACEUTICALS, INC. (ALNY)
As-reported financials and recent SEC filings for ALNYLAM PHARMACEUTICALS, INC., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$3.71B
Net income
$313.7M
Net margin
8.4%
Diluted EPS
$2.33
ROE
39.8%
P/E (TTM)
73.0×
Market cap
$38.90B
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $2.25B | $1.83B | $1.04B | $844.3M |
| Gross profit | $3.04B | $1.94B | $1.56B | $897.2M | $729.3M |
| Operating income | $501.6M | $-176.9M | $-282.2M | $-785.1M | $-708.7M |
| Net income | $313.7M | $-278.2M | $-440.2M | $-1.13B | $-852.8M |
| Diluted EPS | $2.33 | $-2.18 | $-3.52 | $-9.30 | $-7.20 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
42026-06-03
View on EDGAR →42026-06-03
View on EDGAR →32026-06-03
View on EDGAR →1442026-06-01
View on EDGAR →8-K2026-05-27
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →42026-05-22
View on EDGAR →Go deeper on ALNY
Search ALNYLAM PHARMACEUTICALS, INC.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeData sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.